Jimmy Tam Huy Pham

Jimmy Tam Huy Pham

Auto-generated profile, based on publicly available information

Jimmy Tam Huy Pham

Department of Internal Medicine, Garden City Hospital, 6245 Inkster Rd, Garden City , USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2008 in Inorganic Chemistry
Verified
Journal Article
Closed access
JZJian Zhang
Jian Zhang
ECEmily Chew
Emily Chew
SCShumei Chen
Shumei Chen
JPJimmy T. H. Pham
Jimmy T. H. Pham
XBXianhui Bu
Xianhui Bu

31 December 2008 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
ABAmy C. Brown
Amy C. Brown
CSChirag Shah
Chirag Shah
JLJessie Liu
Jessie Liu
JPJimmy T. H. Pham
Jimmy T. H. Pham
JZJian Gang Zhang
Jian Gang Zhang
MJMartin R. Jadus
Martin R. Jadus

18 September 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JPJimmy Pham
Jimmy Pham
BBBill Brownlow
Bill Brownlow
Tamer ElbayoumiTamer Elbayoumi
Tamer Elbayoumi

1 February 2015 in International Journal of Nanomedicine
Verified
Journal Article
Open access
Tamer ElbayoumiTamer Elbayoumi
Tamer Elbayoumi
AGAmy Gavin
Amy Gavin
JPJimmy Tam Huy Pham
Jimmy Tam Huy Pham
DWDawei Wang
Dawei Wang
BBBill Brownlow
Bill Brownlow
Oral cavity and oropharyngeal cancers are considered the eighth most common cancer worldwide, with relatively poor prognosis (62% of patients surviving 5 years, after diagnosis). The aim of this study was to develop a proof-of-concept mucoadhesive lozenge/buccal tablet, as a potential platform for direct sustained delivery of therapeutic antimitotic nanomedicines. Our system would serve as an adjuvant therapy for oral cancer patients undergoing full-scale diagnostic and operative treatment plans. We utilized lipid-based nanocarriers, namely nanoemulsions (NEs), containing mixed-polyethoxylated emulsifiers and a tocopheryl moiety–enriched oil phase. Prototype NEs, loaded with the proapoptotic lipophilic drug genistein (Gen), were further processed into buccal tablet formulations. The chitosan polyelectrolyte solution overcoat rendered NE droplets cationic, by acting as a mucoadhesive interfacial NE layer. With approximate size of 110 nm, the positively charged chitosan-layered NE (+25 mV) vs negatively charged chitosan-free/primary aqueous NE (-28 mV) exhibited a controlled-release profile and effective mucoadhesion for liquid oral spray prototypes. When punch-pressed, porous NE-based buccal tablets were physically evaluated for hardness, friability, and swelling in addition to ex vivo tissue mucoadhesion force and retention time measurements. Chitosan-containing NE tablets were found equivalent to primary NE and placebo tablets in compression tests, yet significantly superior in all ex vivo adhesion and in vitro release assays (P≤0.05). Following biocompatibility screening of prototype chitosan-layered NEs, substantial anticancer activity of selected cationic Gen-loaded NE formulations, against two oropahryngeal carcinomas, was observed. The data strongly indicate the potential of such nanomucoadhesive systems as maintenance therapy for oral cancer patients awaiting surgical removal, or postresection of identified cancerous lesions.

15 October 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NHNeil Hoa
Neil Hoa
LGLisheng Ge
Lisheng Ge
YKYurii Kuznetsov
Yurii Kuznetsov
AMAlex McPherson
Alex McPherson
ACAndrew N Cornforth
Andrew N Cornforth
MJMartin R Jadus
Martin R Jadus
Gliomas are invasive cancers that resist all forms of attempted therapy. Immunotherapy using Ag-pulsed dendritic cells has improved survival in some patients. We present evidence that another level of complexity may also contribute to lack of responses by the lymphocytes toward gliomas. Atomic force microscopy of four different glioma types—human U251 and rat T9 and F98 glioma cells, including freshly isolated human glioblastoma multiforme neurosphere cultures (containing “stem cell-like cells”)—revealed a complex surface topography with numerous microvilli and filopodia. These structures were not found on other cell types. Electron microscopy and immunofluorescence microscopy of glioma cells confirmed that microvilli are present. U251 cells with microvilli resisted the cytolytic actions of different human effector cells, (lymphokine-activated killer cells, γδ T cells, conventional CTLs, and chimeric Ag-receptor–redirected T cells) better than their nonmicrovilli-expressing counterparts. Killer lymphocytes released perforin, which was detected within the glioma’s microvilli/filopodia, indicating these structures can receive the cytolytic effector molecules, but cytotoxicity is suboptimal. Air-dried gliomas revealed nodes within the microvilli/filopodia. The microvilli that penetrated 0.4-μm transwell chamber’s pores resisted the actions of CTLs and physical damage. Those nodelike structures may represent a compartmentalization that resists physical damage. These microvilli may play multiple roles in glioma biology, such as invasion and resistance to lymphocyte-mediated killing.

8 October 2014 in Drug Delivery
Verified
Journal Article
Closed access
JPJimmy Pham
Jimmy Pham
ANAmy Nayel
Amy Nayel
CHChristina Hoang
Christina Hoang
Tamer ElbayoumiTamer Elbayoumi
Tamer Elbayoumi
The potent anti-proliferative and pro-apoptotic actions of tocotrienols (T3) against cancer, but not normal tissues, have been hampered by their limited systemic bioavailabilty. Recent expansive development of diverse nanoemulsion (NE) vehicles emphasized their vast potential to improve the effective dosing of different clinical and experimental drugs of lipophilic nature, such as T3. The emphasis of the present work is to develop a pharmaceutically scalable, low-energy nano-emulsification approach for optimized incorporation of T3-rich palm oil (Tocomin®), possessing anticancer activity as a potential cutaneous delivery platform for adjunctive therapy of skin carcinomas, either alone or in combination with other chemotherapeutic agents. Different Tocomin®-NEs, obtained with different homogenization strategies, were screened based on physicochemical uniformity (droplet size, charge and polydispersity) and subjected to stress physical stability testing, along with chemical content analysis (≥90% Tocomin® - incorporation efficiency). Adopted hybrid nano-emulsification of Tocomin®, correlated with highest preservation of DPPH-radical scavenging capacity of active T3 in prototype formulation, Tocomin®-NE, which effectively permeated diffusion cell membranes 4-folds higher than propyleneglycol (PG)-admixed Tocomin® control. Against two different cell models of human cutaneous carcinoma, Tocomin®-hybrid NE demonstrated significantly stronger cytotoxic profiles (p ≤ 0.01), visible in both concentration- and time- dependent manners, with at least 5-folds lower IC50 values, compared to those estimated for the closest Tocomin®-control. The proposed hybrid nano-emulsified formulation of Tocomin® provides simple and stable delivery platform, for effective topical application against keratinocyte tumors.